NCT04541329

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

Detailed description

This is a one-arm, open-label study to examine the effect of Tildrakizumab. Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis. This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions. Fifteen subjects with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
BIOLOGICAL	Tildrakizumab	IL-23 inhibitor

Timeline

• Start date: 2020-09-16
• Primary completion: 2023-01-15
• Completion: 2023-01-15
• First posted: 2020-09-09
• Last updated: 2024-04-30
• Results posted: 2024-04-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study